Trial Profile
A PHASE I OPEN-LABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB (MDV3800) IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 02 Mar 2022 Results published in the British Journal of Clinical Pharmacology
- 17 Sep 2021 Results (n=37) of population PK analysis using plasma PK data from patients enrolled in this trial presented at the 2021 American College of Clinical Pharmacology Annual Meeting
- 11 Aug 2020 Status changed from recruiting to completed.